2018 American Transplant Congress
The Value of Serum Dilution on DSA Outcome Analysis in Renal Transplantation
Background: Recently, transplant centers have discussed the potential value of sera dilutions in assessment of donor specific anti-HLA antibodies (DSA). However, to date, no data…2018 American Transplant Congress
Successful Utilization of Deceased Donor Kidney Allografts with KDPI>85: The Organ is Not Wholly to Blame
Background: High kidney donor profile index (KDPI)>85% organs are increasingly discarded, suggesting missed opportunities to provide patients the benefits of transplantation. Herein, we report the…2018 American Transplant Congress
Use of Perfusion Machine after Long Cold Ischemia Time: 3 Years Results
The rate of delayed graft function (DGF) in Brazil is very high, reaching 80%. This is due to the long cold ischemia time (TIF) and…2018 American Transplant Congress
Infectious Complications Associated with Eculizumab Used for ABO-Incompatible Renal Transplantation
University of Illinois at Chicago, Chicago.
Introduction: A novel approach in ABO-incompatible (ABOi) living donor renal transplant (LDRT) includes use of eculizumab (ECU) that allows for avoidance of traditional desensitization. We…2018 American Transplant Congress
Multivariate Cox Proportional Hazards Model for Estimating Long-Term Risk of Aging Kidney Transplant Recipients
Henry Ford Transplant Institute, Detroit, MI.
Purpose: The growing number of elderly kidney transplant recipients (KTR) presents an opportunity to analyze and predict long-term outcomes and risk in this aging population.Methods:…2018 American Transplant Congress
Delivery of Culturally-Competent Transplant Care among Hmong Kidney Transplant Recipients: Outcomes from a Single Institution
OBJECTIVE: Kidney transplantation (KT) entails delivery of complex, well-coordinated, multidisciplinary care. Cultural and linguistic discordance among transplant providers and patients can lead to healthcare disparities.…2018 American Transplant Congress
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study
1TRANSFORM Study Group, Barcelona, Spain; 2Novartis Pharma AG, Basel, Switzerland.
Purpose: TRANSFORM (NCT01950819) is the largest study conducted in de novo kidney transplant recipients (KTxRs) to evaluate the benefit of everolimus with reduced-dose calcineurin inhibitor…2018 American Transplant Congress
Epitope/Eplet Mismatch in Pediatric Renal Transplantation and Development of Donor Specific Antibody
Background: De-novo donor specific antibody (DSA) is one of the strongest independent predictors of graft loss with HLA mismatching being a major risk factor for…2018 American Transplant Congress
Determining the Relative Immunogenicity of HLA Mismatches with Calcineurin Inhibitor Immunosuppression: An Analysis of the BENEFIT and BENEFIT-EXT Renal Transplant Cohort
We studied the relative immunogenicity of HLA-A, -B, -C, -DR and -DQ MM (serological) in a cohort of 291 kidney transplant patients from the BENEFIT…2018 American Transplant Congress
Ciprofloxacin for BK Viremia Prophylaxis in Kidney Transplant Recipients: Results of a Prospective, Randomized Controlled Trial
Houston Methodist Hospital, Houston, TX.
Fluoroquinolone (FQ) antibiotics have in vitro activity against BK virus, with several reports indicating they may reduce the risk of BK infection in kidney transplant…
- « Previous Page
- 1
- …
- 299
- 300
- 301
- 302
- 303
- …
- 531
- Next Page »